Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Menkes disease (MD) is a rare and grave multisystemic disorder characterized by disruptions in copper metabolism. This condition, which primarily affects males due to its X-linked recessive inheritance pattern, is associated with progressive neurodegeneration, connective tissue abnormalities, and distinctive 'kinky' hair. The underlying cause of MD lies in mutations within the ATP7A gene, with most of these mutations manifesting as intragenic alterations or partial gene deletions. The ATP7A gene plays a crucial role as an energy-dependent transmembrane protein responsible for transporting copper to secreted copper enzymes while expelling excess copper from cells. This intricate process ensures the delicate balance of copper within the body, and any mutations in ATP7A can lead to the severe and life-threatening consequences observed in Menkes disease. MD primarily affects males, with most patients succumbing to the disease before reaching their third year of life. The multisystemic impact of MD includes progressive neurodegeneration, resulting in severe neurological symptoms. Additionally, connective tissue disturbances contribute to the clinical manifestations of the disease. The peculiar 'kinky' hair is a distinctive external marker of Menkes disease.

·       Incidence estimates for Menkes disease in the USA range from 0.75 to 1.27 cases per 100,000 live births, highlighting its rarity. There is currently no cure for Menke's disease. However, early intervention with copper-histidine treatment, administered very early during the disease, may relieve neurological symptoms.

 

Thelansis’s “Menkes Disease (MD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menkes Disease (MD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Menkes Disease (MD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Menkes Disease (MD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Menkes Disease (MD), Menkes Disease (MD) market outlook, Menkes Disease (MD) competitive landscape, Menkes Disease (MD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)